Certara(US:CERT) Newsfilter·2025-04-01 12:00Core Insights - Certara, Inc. has launched a new version of the Simcyp™ Simulator, enhancing its capabilities for physiologically-based pharmacokinetic (PBPK) modeling to support data-driven decision-making in drug development [1][2] Company Developments - The Simcyp Simulator Version 24 has been developed with input from a consortium of over 30 leading pharmaceutical companies, reflecting the evolving needs of pharmaceutical collaborators and regulators [2] - The simulator has been instrumental in the approval of over 120 novel drugs by the FDA and has facilitated clinical trial waivers in various areas, including drug-drug interactions (DDI) and pediatric trials [3] Technological Advancements - The latest version includes features for predicting food effects on drug absorption, expanded libraries for drug-drug interactions, and improved modeling for special populations such as pediatrics, pregnancy, and lactation [4] - Enhancements in performance and usability include a modernized user interface, cloud computing capabilities, and AI-enabled help chat [4] Market Impact - Currently, 80% of drugs utilizing PBPK for FDA approval in recent years have employed the Simcyp Simulator, indicating its significant role in the industry [2]